New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
09:45 EDTOREX, ARNA, VVUSVIVUS, Arena, Orexigen move higher in early trading
The makers of obesity drugs are moving higher in early trading. The strength is being attributed to speculation of expanded coverage by insurers.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
07:19 EDTVVUSVIVUS issued two patents for Qsymia
Subscribe for More Information
November 25, 2014
09:39 EDTARNAActive equity options trading
Subscribe for More Information
08:06 EDTARNAArena Pharmaceuticals granted patent covering ralinepag
Arena Pharmaceuticals announced that the US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776, entitled "Modulators of the Prostacyclin Receptor Useful for the Treatment of Disorders Related Thereto," covering ralinepag, an orally available agonist of the prostacyclin, or IP, receptor. Ralinepag is an investigational drug candidate being developed by Arena for the treatment of vasospastic diseases such as pulmonary arterial hypertension.
November 21, 2014
09:17 EDTOREXOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTOREXOrexigen announces allowance of new U.S. patent for Contrave
Orexigen Therapeutics announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for U.S. Patent Application No. 11/757,773, which covers use of Orexigen's sustained release formulation of naltrexone, which was designed to improve drug tolerability for Contrave in a method for treating obesity. The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the FDA.
November 18, 2014
07:37 EDTARNAStifel to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use